Search Results 2041-2050 of 20153 for Receptor

1. A Study to Better Understand Why Patients Gain Weight After Undergoing Liver Transplantation - Mayo Clinic

   ... receptor or amylin agonists in patients with diabetes mellitus. Stable doses of anti-rejection therapy, Bactrim, Acyclovir/Valganciclovir, proton pump ...

2. Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer - Mayo Clinic

   Estrogen receptor (ER) positive disease according to ASCO/CAP guidelines as ER≥1% positive nuclear staining. Completion of all planned cancer treatments ...

3. A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis - Mayo Clinic

   Participation eligibility · Prior use of any biologic therapy targeting interleukin (IL)-12/23, IL-17, or IL-23 receptor. · Use of non-steroidal anti-inflammatory ...

4. Monoclonal antibody medicines for cancer: How they work - Mayo Clinic

   If your healthcare professional recommends a monoclonal antibody medicine as part of your cancer treatment, find out what to expect from this therapy. Learn ...

5. A Study of Sporadic Angiomyolipomas Growth Kinetics While on Everolimus - Mayo Clinic

   Renal Function epidermal growth factor receptor (eGFR) ≥ 30 mL/min via calculated creatinine clearance; Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 ...

6. Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery - Mayo Clinic

   Patients who have received cetuximab or another inhibitor of epidermal growth factor receptor (EGFR) in the curative intent treatment setting (e.g. with ...

7. Effectiveness and Safety of Pembrolizumab for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer - Mayo Clinic

   Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor. Has ...

8. NAFLD and NASH research update - Mayo Clinic

   OCA is a modified bile acid that is a farnesoid X receptor (FXR) agonist. Conducted at Mayo Clinic's campuses in Arizona and Minnesota, this trial looks at ...

9. Neurology - Doctors - Mayo Clinic

   ... receptor antibody encephalitis, Meningoencephalitis, Myelitis. Show more areas of focus for M Mateo Paz Soldan, M.D., Ph.D. Jeffrey B ...

10. Choosing blood pressure medicines - Mayo Clinic

    Angiotensin 2 receptor blockers. Also called ARBs, these medicines block the action of angiotensin. Angiotensin is a chemical the body makes that narrows ...